Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Deloitte
Healthtrust
Covington
McKinsey
Julphar
Mallinckrodt
Medtronic
Chubb
Dow

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,125,875

« Back to Dashboard

Which drugs does patent 7,125,875 protect, and when does it expire?

Patent 7,125,875 protects SPRYCEL and is included in one NDA.

This patent has sixty-nine patent family members in thirty-eight countries.
Summary for Patent: 7,125,875
Title:Cyclic protein tyrosine kinase inhibitors
Abstract:Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Inventor(s): Das; Jagabandhu (Mercerville, NJ), Padmanabha; Ramesh (Hamden, CT), Chen; Ping (Belle Mead, NJ), Norris; Derek J. (Trenton, NJ), Doweyko; Arthur M. P. (Long Valley, NJ), Barrish; Joel C. (Richboro, PA), Wityak; John (Robbinsville, NJ), Lombardo; Louis J. (Belle Mead, NJ), Lee; Francis Y. F. (Yardley, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/395,503
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,125,875

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR THE TREATMENT OF CANCER ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR THE TREATMENT OF CANCER ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-003 Jun 28, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR THE TREATMENT OF CANCER ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-003 Jun 28, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR THE TREATMENT OF CANCER ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD FOR THE TREATMENT OF CANCER ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,125,875

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,596,746 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
7,153,856 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
7,189,854 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
8,993,567 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
9,382,219 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
8,716,323 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
6,979,694 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
7,091,223 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,125,875

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 87456 ➤ Sign Up
Taiwan I351404 ➤ Sign Up
Taiwan 200510403 ➤ Sign Up
Turkey 200102969 ➤ Sign Up
Slovenia 1610780 ➤ Sign Up
Russian Federation 2365372 ➤ Sign Up
Russian Federation 2005132408 ➤ Sign Up
Russian Federation 2312860 ➤ Sign Up
Russian Federation 2005107463 ➤ Sign Up
Russian Federation 2260592 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
McKesson
QuintilesIMS
Baxter
Moodys
Cerilliant
Farmers Insurance
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot